Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Oncopeptides AB ( (SE:ONCO) ) is now available.
Oncopeptides AB announced the successful completion of its rights issue, which was oversubscribed by approximately 157 percent, raising around SEK 150 million. This financial boost is expected to enhance the company’s operational capabilities and strengthen its market position, with new shares set to begin trading on Nasdaq Stockholm by late September 2025.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a pharmaceutical company based in Stockholm, Sweden, specializing in the development of therapies for difficult-to-treat hematological diseases. The company focuses on innovative cancer treatments, particularly targeting multiple myeloma.
Average Trading Volume: 6,330,439
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.32B
See more insights into ONCO stock on TipRanks’ Stock Analysis page.